New FDA approved prostate cancer therapy.
Posted by giorgiobertin on June 25, 2023
The new treatment combines two anticancer drugs, enzalutamide e talazoparib (Talzenna, Pfizer, Inc.) While enzalutamide is a drug typically used for prostate cancer, the addition of talazoparib is new in prostate cancer patients. In one phase 3 studythis drug combination was found to reduce the risk of cancer progression by 55%, compared with standard treatment.
“The FDA’s approval of the talazoparib and enzalutamide combination is based on the findings from the pivotal TALAPRO-2 study, which demonstrated statistically significant and clinically meaningful reductions in the risk of progression or death among HRR gene-mutated tumors in patients with metastatic castration-resistant prostate cancer. It represents a treatment option deserving of excitement and attention,” said Neeraj Agarwal, MD, global lead investigator for TALAPRO-2.
On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutation. The phase 3 study TALAPRO-2.
Read abstract of the article:
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, et al.
The Lancet. 2023;0(0). doi:10.1016/S0140-6736(23)01055-3
ClinicalTrials.gov (NCT03395197)
View full prescribing information for Talzenna
Sources: Huntsman Cancer Institute – Urologytimes.com
I like:
“Like” Loading…
Related
This entry was posted on giugno 25, 2023 a 6:51 am and is filed under News-search. Marked by tags: pharmacology, oncology, urology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.